SCHEMBL4338968

SCHEMBL4338968

Cc1cc(O)c2ccccc2c1OP(=O)(O)O.[NaH]

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 3/20 0.58
MAPT P10636 3/20 0.58
KDM4E B2RXH2 2/20 0.58
GAA P10253 2/20 0.58
TP53 P04637 1/20 0.58
HSD17B10 Q99714 1/20 0.58
LMNA P02545 2/20 0.49
SRC P12931 4/20 0.46
INPPL1 O15357 6/20 0.41
INPP5A Q14642 5/20 0.41
INPP5B P32019 2/20 0.41
AKT1 P31749 1/20 0.39
POLB P06746 2/20 0.37
MEN1 O00255 1/20 0.37
NSD2 O96028 1/20 0.37
KMT2A Q03164 1/20 0.37
MCL1 Q07820 1/20 0.37
EP300 Q09472 1/20 0.36
PTPN1 P18031 1/20 0.36
TRPM4 Q8TD43 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10915218 0.88 HTT (0.52) HTTMAPTKDM4EGAATP53
SCHEMBL7534018 0.84 MAPT (0.58) HTTMAPTKDM4EGAATP53
Menadiol Diphosphoric Acid SCHEMBL515181 0.82 HTT (0.51) HTTMAPTKDM4EGAATP53
Vitamin K3H2 SCHEMBL27560223 0.76 HTT (0.78) HTTMAPTKDM4EGAATP53
SCHEMBL9812714 0.75 KDM4E (0.64) HTTMAPTKDM4EGAATP53
Vitamin K3H2 SCHEMBL9223417 0.75 HTT (0.70) HTTMAPTKDM4EGAATP53
Vitamin K3H2 SCHEMBL987810 0.75 HTT (0.75) HTTMAPTKDM4EGAATP53
SCHEMBL25297948 0.74 SRC (0.53) HTTMAPTKDM4EGAATP53
Vitamin K3H2 SCHEMBL515182 0.74 HTT (0.81) HTTMAPTKDM4EGAATP53
SCHEMBL18327129 0.74 KDM4E (0.62) HTTMAPTKDM4EGAATP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10987501-B2 Cell impregnated sleeve for paracrine and other factor production THE JOHNS HOPKINS UNIVERSITY (US) 2021-04-27 US disclosed
US-10940088-B1 Method of preparing low dose pharmaceutical formulations KING SAUD UNIVERSITY (SA) 2021-03-09 US disclosed
US-20200147358-A1 CELL IMPREGNATED SLEEVE FOR PARACRINE AND OTHER FACTOR PRODUCTION UNIV JOHNS HOPKINS (US) 2020-05-14 US disclosed
US-10561830-B2 Cell impregnated sleeve for paracrine and other factor production THE JOHNS HOPKINS UNIVERSITY (US) 2020-02-18 US disclosed
US-20160235956-A1 CELL IMPREGNATED SLEEVE FOR PARACRINE AND OTHER FACTOR PRODUCTION THE JOHNS HOPKINS UNIVERSITY 2016-08-18 US disclosed
WO-2015054183-A1 CELL IMPREGNATED SLEEVE FOR PARACRINE AND OTHER FACTOR PRODUCTION THE JOHNS HOPKINS UNIVERSITY (US) 2015-04-16 WO disclosed
US-20140364368-A1 STIMULUS RESPONSIVE NANOCOMPLEXES AND METHODS OF USE THEREOF NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2014-12-11 US disclosed
WO-2014197816-A1 STIMULUS RESPONSIVE NANOCOMPLEXES AND METHODS OF USE THEREOF MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2014-12-11 WO disclosed
US-8486374-B2 Alcohol-free drug or cosmetics carrier mixture of water, hydrophobic solvent, surfactant and gelling agent; oil in water emulsions FOAMIX LTD. (IL) 2013-07-16 US disclosed
US-7605179-B2 Napthoquinone derivatives as inhibitors of tau aggregation for the treatment of alzheimer's and related neurodegenerative disorders WISTA LABORATORIES LTD. (SG) 2009-10-20 US disclosed
US-20080292560-A1 SILICONE IN GLYCOL PHARMACEUTICAL AND COSMETIC COMPOSITIONS WITH ACCOMMODATING AGENT FOAMIX PHARMACEUTICALS LTD. (IL) 2008-11-27 US disclosed
US-20080206161-A1 QUIESCENT FOAMABLE COMPOSITIONS, STEROIDS, KITS AND USES THEREOF FOAMIX PHARMACEUTICALS LTD. (IL) 2008-08-28 US disclosed
US-20080069779-A1 Foamable vehicle and vitamin and flavonoid pharmaceutical compositions thereof FOAMIX LTD. (IL) 2008-03-20 US disclosed
EP-1408952-B1 NAPTHOQUINONE DERIVATIVES AS INHIBITORS OF TAU AGGREGATION FOR THE TREATMENT OF ALZHEIMER'S AND RELATED NEURODEGENERATIVE DISORDERS WISTA LAB LTD (SG) 2007-05-02 EP disclosed
US-20050107472-A1 Napthoquinone derivatives as inhibitors of tau aggregation for the treatment of alzheimer's and related neurodegenerative disorders THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN (GB) 2005-05-19 US disclosed
EP-1408952-A1 NAPTHOQUINONE DERIVATIVES AS INHIBITORS OF TAU AGGREGATION FOR THE TREATMENT OF ALZHEIMER'S AND RELATED NEURODEGENERATIVE DISORDERS The University Court of The University of Aberdeen (GB) 2004-04-21 EP disclosed
WO-2003007933-A1 NAPTHOQUINONE DERIVATIVES AS INHIBITORS OF TAU AGGREGATION FOR THE TREATMENT OF ALZHEIMER'S AND RELATED NEURODEGENERATIVE DISORDERS THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN (GB) 2003-01-30 WO disclosed
EP-0182765-B1 ELECTROCHEMICAL CONTROLLED RELEASE DRUG DELIVERY SYSTEM THE REGENTS OF THE UNIVERSITY OF MINNESOTA (US) 1992-08-26 EP disclosed
EP-0182765-A2 Electrochemical controlled release drug delivery system THE REGENTS OF THE UNIVERSITY OF MINNESOTA (US) 1986-05-28 EP disclosed
US-4585652-A REDOX SITES ON CHARGED POLYMER REGENTS OF THE UNIVERSITY OF MINNESOTA (US) 1986-04-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080206161-A1 QUIESCENT FOAMABLE COMPOSITIONS, STEROIDS, KITS AND USES THEREOF NR5A1, CYP17A1, LIPA HTT 3149/4885MAPT 4587/4885KDM4E 362/4885
US-20080292560-A1 SILICONE IN GLYCOL PHARMACEUTICAL AND COSMETIC COMPOSITIONS WITH ACCOMMODATING AGENT SSTR2, SSTR3, LPXN HTT 498/4885MAPT 1240/4885KDM4E 4521/4885
US-20080069779-A1 Foamable vehicle and vitamin and flavonoid pharmaceutical compositions thereof PROC, VKORC1, TTPA HTT 188/4885MAPT 1551/4885KDM4E 3332/4885
US-20050107472-A1 Napthoquinone derivatives as inhibitors of tau aggregation for the treatment of alzheimer's and related neurodegenerative disorders MAPT, PSEN1, PSEN2 HTT 45/4885MAPT 1/4885KDM4E 3803/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.